Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Insomnia

Insomnia

Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...

Sedatives and Hypnotics: Overview

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

CNS Depressants: Barbiturates and Benzodiazepines

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The association between mental health disorders and allergic reactions: a multicenter retrospective analysis.

Journal of psychiatric research·2026

Same author

Comparison of long-acting injectable antipsychotics with oral antipsychotics and hospital readmission rates in pediatric patients.

The mental health clinician·2024

Same author

Evaluation of Interprofessional Education on Effective Communication Between Pharmacy and Physician Assistant Students.

The journal of physician assistant education : the official journal of the Physician Assistant Education Association·2022

Same author

Pharmacotherapy treatment of stimulant use disorder.

The mental health clinician·2021

Same author

Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil.

The mental health clinician·2019

Same author

Evaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongation.

The mental health clinician·2018

Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026

Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026

Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026

Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026

Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026

Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 24, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

Current and emerging therapies for insomnia.

¹Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ; Department of Pharmacy, Penn Medicine Princeton House Behavioral Health, Princeton, NJ.

The American Journal of Managed Care

|April 14, 2020

Summary

This summary is machine-generated.

Chronic insomnia affects up to 10% of US adults, particularly women and the elderly. This review covers pharmacotherapeutic options beyond cognitive behavioral therapy, including newer orexin inhibitors.

More Related Videos

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Dec 24, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Area of Science:

Sleep Medicine
Pharmacology

Background:

Chronic insomnia affects up to 10% of US adults, with higher prevalence in women and the elderly.
Cognitive behavioral therapy is the primary treatment, but pharmacotherapy is often necessary when it is insufficient.
Traditional insomnia medications include benzodiazepines and nonbenzodiazepine GABA-A receptor agonists.

Purpose of the Study:

To review current and emerging pharmacotherapeutic options for treating chronic insomnia.
To discuss the role of newer agents like orexin inhibitors in insomnia management.
To provide an overview of available medications for overcoming sleep barriers.

Main Methods:

Literature review of pharmacotherapeutic agents for insomnia.
Analysis of approved and investigational insomnia medications.
Discussion of medication classes including traditional and novel agents.

Main Results:

Suvorexant and lemborexant are currently approved orexin inhibitors for insomnia.
Orexin inhibitors may offer improved safety profiles, including reduced dependence potential.
Several other orexin receptor antagonists are in late-stage development.

Conclusions:

Pharmacotherapy plays a crucial role in managing chronic insomnia when behavioral therapies are insufficient.
Orexin inhibitors represent a significant advancement in insomnia pharmacotherapeutics.
The landscape of insomnia treatment is evolving with new agents offering potentially better efficacy and safety profiles.